Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:DAWNOTCMKTS:NWPHFNASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$22.45-0.5%$19.73$12.21▼$41.31$653.12M-0.2611,542 shs683,007 shsDAWNDay One Biopharmaceuticals$6.39-1.4%$7.04$6.08▼$16.76$647.70M-1.241.11 million shs1.21 million shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/ATRVITrevi Therapeutics$6.50+2.2%$6.24$2.30▼$7.39$649.30M0.621.22 million shs1.45 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%+9.83%+5.95%+53.35%-6.22%DAWNDay One Biopharmaceuticals0.00%+1.91%-19.42%-22.55%-51.85%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%-22.00%TRVITrevi Therapeutics0.00%+3.34%-7.01%+52.58%+152.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.7809 of 5 stars4.41.00.00.02.81.70.6DAWNDay One Biopharmaceuticals2.6211 of 5 stars4.60.00.00.02.92.50.0NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics3.6183 of 5 stars4.73.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.70Moderate Buy$40.3879.84% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57378.43% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/ATRVITrevi Therapeutics 3.30Buy$18.63186.54% UpsideCurrent Analyst Ratings BreakdownLatest NWPHF, ANAB, TRVI, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.005/20/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M5.90N/AN/A$3.32 per share6.76DAWNDay One Biopharmaceuticals$161.92M4.00N/AN/A$3.98 per share1.61NWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics-$29.07M-$0.45N/AN/AN/AN/A-63.31%-57.06%8/14/2025 (Estimated)Latest NWPHF, ANAB, TRVI, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025TRVITrevi Therapeutics-$0.13-$0.09+$0.04-$0.09N/AN/A5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million3/18/2025Q4 2024TRVITrevi Therapeutics-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A10.2310.23DAWNDay One BiopharmaceuticalsN/A14.6214.55NWPHFNewron PharmaceuticalsN/AN/AN/ATRVITrevi TherapeuticsN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ADAWNDay One Biopharmaceuticals87.95%NWPHFNewron PharmaceuticalsN/ATRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%DAWNDay One Biopharmaceuticals6.20%NWPHFNewron PharmaceuticalsN/ATRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million20.17 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableTRVITrevi Therapeutics2099.89 million58.13 millionOptionableNWPHF, ANAB, TRVI, and DAWN HeadlinesRecent News About These CompaniesTrevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral CapitalJune 2 at 8:17 AM | marketbeat.comTrevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 2 at 7:00 AM | prnewswire.comTrevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic CoughJune 1 at 4:00 PM | prnewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by AnalystsJune 1 at 3:48 AM | marketbeat.comWhat is HC Wainwright's Forecast for TRVI Q2 Earnings?June 1 at 1:21 AM | americanbankingnews.comResearch Analysts Issue Forecasts for TRVI Q2 EarningsMay 31 at 5:52 AM | marketbeat.comHC Wainwright Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)May 30 at 1:21 AM | americanbankingnews.comH.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy RatingMay 29, 2025 | msn.comTrevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Still a Buy?May 29, 2025 | marketbeat.comHC Wainwright Begins Coverage on Trevi Therapeutics (NASDAQ:TRVI)May 29, 2025 | marketbeat.comTrevi Therapeutics to Participate in Upcoming June ConferencesMay 29, 2025 | prnewswire.comNorthern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 27, 2025 | marketbeat.comWoodline Partners LP Buys 2,606,370 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Boosts Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 23, 2025 | marketbeat.comTrevi Therapeutics' (TRVI) Buy Rating Reiterated at Needham & Company LLCMay 23, 2025 | americanbankingnews.comNeedham & Company LLC Reaffirms "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)May 22, 2025 | marketbeat.comVR Adviser LLC Reduces Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 22, 2025 | marketbeat.comTrevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic CoughMay 20, 2025 | prnewswire.comPoint72 Asset Management L.P. Takes Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $368,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWPHF, ANAB, TRVI, and DAWN Company DescriptionsAnaptysBio NASDAQ:ANAB$22.45 -0.11 (-0.49%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$22.23 -0.22 (-0.98%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWN$6.39 -0.09 (-1.39%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$6.45 +0.06 (+0.94%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 05/30/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Trevi Therapeutics NASDAQ:TRVI$6.50 +0.14 (+2.20%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$7.15 +0.65 (+10.00%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
